BioPharmX to present evidence that BPX-01 topical minocycline gel may reduce acne-associated inflammation
- Research finds topical minocycline demonstrates non-antibiotic, anti-inflammatory effects
- Topical application may be effective against P. acnes-stimulated inflammation
MENLO PARK, Calif., Dec. 7, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share research at the Antibacterial Discovery and Development Summit in Boston that suggests topical delivery of minocycline may be effective for the treatment of acne because, in topical form, minocycline may fight P. acnes-induced local inflammation.
The study, which for the first time evaluates topical minocycline efficacy in a murine model of acne, suggested that a topical formulation effectively delivered minocycline into the skin and improved efficacy against P. acnes. Results will be showcased in a poster Thursday.
Presentation Details:
Title: "Therapeutic Effects of a Topical Minocycline in an Inflammatory Skin Disorder Animal Model,"
Presenter: Usha Nagavarapu, Ph.D.
Location: The Revere Hotel, Boston
Time: 9:35 a.m. ET
The research is notable because it represents the first analysis of minocycline's impact on inflammatory acne-like lesions in an animal model. Previous studies have focused on P. acnes reduction and acne lesion reduction rather than the P. acnes-related inflammation that may cause or aggravate acne.
"Minocycline is a proven anti-inflammatory drug and commonly used to treat moderate-to-severe acne," said G. Scott Herron, a board-certified dermatologist and fellow of the American Academy of Dermatology. "Minocycline's anti-inflammatory benefits may be even more effective when delivered in a low dose topical formulation as the delivery is both targeted and localized."
BPX-01, BioPharmX's unique topical minocycline gel formulation is the first and only stable hydrophilic (non-oil-based) topical gel with fully solubilized minocycline that can penetrate the skin to deliver the antibiotic to the layer of skin where the acne develops in the pilosebaceous unit.The company's studies are designed to confirm whether BPX-01 will effectively treat acne with lower, and potentially safer, dosages of the antibiotic.
BioPharmX recently initiated a Phase 2b dose-finding study, called the OPAL Trial (tOPicAL minocycline gel), that is a 12-week, multi-center, randomized, double-blind, three-arm, vehicle controlled study and will enroll 225 subjects, aged 9 to 40, with moderate-to-severe inflammatory, non-nodular acne vulgaris.
The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting 40 million to 50 million Americans. The U.S. market for acne medications is estimated at $10 billion
